BaxitozineAlternative Names: RU 38086
Latest Information Update: 30 Aug 1994
At a glance
- Originator Aventis
- Developer Roussel-Maestretti
- Class Antisecretories; Cytoprotectives; Small molecules
- Mechanism of Action Histamine H2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Gastric ulcer; Peptic ulcer
Most Recent Events
- 30 Aug 1994 Discontinued-II for Gastric ulcer in Italy (PO)
- 30 Aug 1994 Discontinued-II for Gastric ulcer in France (PO)